Study of some common biochemical bone turnover markers in postmenopausal women

Sachdeva, Ashuma; Seth, Shashi; Khosla, Anju Huria; Sachdeva, Sumit

doi:10.1007/bf02893058

Cited by 30 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case group showed significantly low serum calcium levels (p = 0.025) raised serum alkaline phosphatase (<0.001) and raised serum osteocalcin levels (<0.001). The positive correlation of age with alkaline phosphatase and negative correlation calcium levels is expected due to higher bone turnover in postmenopausal women and has been reported by other researchers also [16][17][18].…”

Section: Resultssupporting

confidence: 68%

Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women

Singh

Kumar

Lal

2015

JCDR

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 68%

Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women

Singh

Kumar

Lal

2015

JCDR

View full text Add to dashboard Cite

“…These factors can degrade collagen type I into hydroxyproline. Our findings were also supported by Indumati et al [14] and Sachdeva et al [5]. Similar observations were also reported by a number of other studies [9,15,16].…”

Section: Resultssupporting

confidence: 93%

“…Thus, the occurrence of osteoporosis in postmenopausal women is very common problem especially in India who is exposed to many of the risk factors [5]. But there are very few Indian studies regarding the prevalence of osteoporosis in postmenopausal women and also regarding the biochemical markers which indicate bone turnover in our setup.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis

Jagtap

Ganu

2011

Ind J Clin Biochem

View full text Add to dashboard Cite

Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of postmenopausal osteoporosis in women. Biochemical markers can enable dynamic and rapid measurement of total body skeletal metabolism and will be clinically useful in the management of postmenopausal osteoporosis women (PMO) and also for assessing the effects of antiresorptive therapy. With this view, we planned to assess osteoclastic activity by determining urinary hydroxyproline in osteoporotic women. The aim of this study is to measure urinary hydroxyproline (expressed as mg of hydroxyproline/g of creatinine) and serum ascorbic acid in postmenopausal women with osteoporosis and without osteoporosis. These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate ? calcium ? vitamin D) in postmenopausal osteoporosis patients. 60 postmenopausal women with osteoporosis in the age group 45-60 years and 60 healthy postmenopausal women (normal bone mineral density) in the same age group were included in the study. Urinary hydroxyproline levels were significantly increased (P \ 0.001) in PMO at baseline level as compared to control group. These levels were decreased significantly (P \ 0.001) post therapy in PMO patients. Serum vitamin C levels were significantly decreased (P \ 0.001) in PMO patients at baseline level as compared to controls. No significant change occurred of serum vitamin C level post therapy. Raised excretion of hydroxyproline at the baseline level might be due to increased degradation of collagen type I from the bone matrix in osteoporosis. Breakdown of collagen seems to be lowered as reflected by lowering of hydroxyproline excretion post antiresorptive therapy. Alteration in the concentration of this marker can be very well utilized to monitor the effectiveness of therapy. Thus simple, direct urinary assay to measure bone resorption is very useful in monitoring the therapy in PMO and may become an integral part of the management of osteoporosis.

show abstract

“…Menopause and ageing is associated with accelerated loss of cortical bone. Bone loss occurs when the balance between formation and V. R. Jagtap (&) Á J. V. Ganu Á N. S. Nagane Department of Biochemistry, Government Medical College, Miraj 416410, Maharashtra, India e-mail: ms.vanita_jagtap@rediffmail.com resorption is upset and resorption is excessive resulting in a negative remodeling balance [4,5].…”

Section: Introductionmentioning

confidence: 99%

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

2010

View full text Add to dashboard Cite

India seems to have the highest prevalence of osteoporosis. With growing awareness of osteoporosis and its impact on life span especially in India, special attention is being paid to early detection, management and treatment of postmenopausal osteoporosis in women. Measurement of BMD and osteocalcin are of value in estimating bone turnover rates. The aim of this study is (1) to measure the specific, sensitive bone formation marker such as osteocalcin and BMD in postmenopausal osteoporosis women and postmenopausal non-osteoporosis women; (2) the follow up study to evaluate the impact of specific antiresorptive therapy (alendronate ? calcium ? vitamin D) regimen in postmenopausal osteoporosis by assaying osteocalcin and BMD. Sixty clinically diagnosed postmenopausal osteoporosis patients and 60 normal subjects (postmenopausal non-osteoporosis women) were recruited as control. Mean bone mineral density T score and Z score was significantly decreased (P \ 0.001) in postmenopausal osteoporosis patients as compared to controls. Highly significant increase in the mean score of BMD-T score and Z score from baseline to post therapy of 3 months was observed in postmenopausal osteoporosis women. Serum osteocalcin levels were significantly increased (P \ 0.001) as compared to control group. Serum osteocalcin levels were decreased significantly (P \ 0.001) from baseline to post therapy of 3 months in postmenopausal osteoporosis women. BMD is the best quantifiable predictor of osteoporotic fracture and osteocalcin is specific, sensitive, promising, currently used marker for better prognosis of osteoporosis and for monitoring responses to antiresorptive therapy.

show abstract

Study of some common biochemical bone turnover markers in postmenopausal women

Cited by 30 publications

References 8 publications

Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women

Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women

Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

Contact Info

Product

Resources

About